3SBio Prepares For Larger Than Expected Price Cuts; Enters Dialysis Market With DaVita Deal: China Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
As price cuts loom, China’s top biotech looks to fuel EPO sales in China by teaming up with a leading U.S. dialysis provider, in a deal reminiscent of Amgen’s steps in the U.S.